The Council for Affordable Health Coverage (CAHC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the memorandum entitled “Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028.”
CAHC’s recommendations included:
- Stop market consolidation that leads to monopolies and higher prices
- Follow the law when selecting drugs under the Inflation Reduction Act and applying rules for orphan drugs
- Fix problems with the Medicare Transaction Facilitator so lower drug prices can take effect at the point of sale
- Make the program transparent, accountable, and open to public input and oversight